N-chloropropionyl-2-pyrrolidone | 84040-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-chloropropionyl-2-pyrrolidone
• 英文别名: 3-(2-oxopyrrolidin-1-yl)propionic acid chloride；3-(2-oxopyrrolidin-1-yl)propanoyl chloride
• CAS: 84040-04-0
• 化学式: C₇H₁₀ClNO₂
• 分子量: 175.615
• InChiKey: ZVVDIHYPZPZXMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-chloropropionyl-2-pyrrolidone 在 叠氮基三甲基硅烷 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以56%的产率得到N-(2-isocyanatoethyl)-2-pyrrolidone
  参考文献：
  名称：

  Gramain, Jean-Claude; Remuson, Roland, Journal of the Chemical Society. Perkin transactions I, 1982, # 10, p. 2341 - 2346

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(2-氧代吡咯烷-1-基) 丙酸甲酯 在 盐酸 、 氯 、 一水合肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-chloropropionyl-2-pyrrolidone
  参考文献：
  名称：

  Gramain, Jean-Claude; Remuson, Roland, Journal of the Chemical Society. Perkin transactions I, 1982, # 10, p. 2341 - 2346

  摘要：

  DOI：

文献信息

• [EN] MODULATORS OF AMYLOID BETA.<br/>[FR] MODULATEURS DE LA PROTÉINE ?-AMYLOÏDE
  申请人：ASTRAZENECA AB

  公开号：WO2010053438A1

  公开（公告）日：2010-05-14

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式I的新化合物及其治疗上可接受的盐，它们的药物组合物，制造它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法的使用。特别是，本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号传导的化合物，并将用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病、唐氏综合症和β-淀粉样蛋白血管病，例如但不限于脑淀粉样血管病、遗传性脑出血、与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或包括混合血管和退行性来源的痴呆在内的疾病相关的神经退行性变、早老性痴呆、老年性痴呆和与帕金森病、进行性核上瘫或皮层基底退行性变相关的痴呆。
• Rhodium(II)-Catalyzed Cyclization of Amido Diazo Carbonyl Compounds
  作者：Albert Padwa、Tadashi Hasegawa、Bing Liu、Zhijia Zhang

  DOI：10.1021/jo0009144

  日期：2000.10.1

  possible to trap some of the initially formed carbonyl ylide dipoles with a reactive dipolarophile such as DMAD. In other cases, cyclization of the dipole to the epoxide is much faster than bimolecular trapping. A related cyclization/rearrangement sequence occurred when diazo ketoamides derived from the cyclic pyrrolidone and piperidone ring systems were subjected to catalytic quantities of Rh(II) acetate

  由N-苯甲酰基-N-烷基氨基丙酸制备了一系列无环重氮酮酰胺，并用催化量的乙酸铑（II）处理。生成的类胡萝卜素在邻近的酰胺羰基氧原子上进行容易的环化反应，生成七元羰基内酯偶极子。偶极子随后随电荷耗散而崩溃，产生了双环环氧化物，该环氧化物会进一步重组，以高收率得到取代的5-羟基二氢吡啶酮。取决于取代基的性质，可以用诸如DMAD的反应性双极性亲和剂捕获一些最初形成的羰基内酯偶极子。在其他情况下，偶极环化成环氧化物的速度比双分子捕获快得多。当衍生自环状吡咯烷酮和哌啶酮环系统的重氮酮酰胺接受催化量的乙酸Rh（II）时，会发生相关的环化/重排序列。在这些系统中，酰胺基团在类胡萝卜素中心发生了排他性的O-环化反应，生成了七环的羰基内酯偶极子。起始原料易于制备，并且级联顺序的收率很高，不需要特殊的预防措施。整个过程代表了一种有效的一锅法，用于合成各种吲哚并咪唑和喹喔啉环系统。起始原料易于制备，并且级联顺序
• COMPOUNDS 563
  申请人：FORSBLOM Rickard

  公开号：US20100130495A1

  公开（公告）日：2010-05-27

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及公式I的新化合物及其治疗上可接受的盐，它们的制药组合物，制备它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法。特别是本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号的化合物，并将其用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病，唐氏综合症和β-淀粉样蛋白血管病，如但不限于脑淀粉样血管病，遗传性脑出血，与认知功能障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆力丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆以及与帕金森病，进行性核上性麻痹或皮层基底节变性相关的痴呆。
• Dihydropyridopyrimidines for the treatment of AB-related pathologies
  申请人：AstraZeneca AB

  公开号：US08188101B2

  公开（公告）日：2012-05-29

  Dihydropyridopyrimidine compounds of formula (Ia) and therapeutically acceptable salts thereof, wherein R1, R2 and Z are as defined in the specification; processes for making them and methods for using them in the treatment of Aβ-related pathologies.

  公式（Ia）的二氢吡啶嘧啶化合物及其治疗上可接受的盐，其中R1，R2和Z如规范中所定义；制备它们的过程以及在治疗Aβ相关病理过程中使用它们的方法。
• GRAMAIN, J. -C.;REMUSON, R., J. CHEM. SOC. PERKIN TRANS. PART 1, 1982, N 10, 2341-2345
  作者：GRAMAIN, J. -C.、REMUSON, R.

  DOI：——

  日期：——